Back to User profile » Prof. Dr. Kyung-Sang Yu

Papers published by Prof. Dr. Kyung-Sang Yu:


Pharmacokinetic Comparison Between a Fixed-Dose Combination of Atorvastatin/Omega-3-Acid Ethyl Esters and the Corresponding Loose Combination in Healthy Korean Male Subjects

Khwarg J, Lee S, Jang IJ, Kang WH, Lee HJ, Kim KY, Jeong KS, Won C, Choi YW, Ha DC, Jung R, Han MG, Jung WT, Nam KY, Kim YS, Yu KS, Oh J

Drug Design, Development and Therapy 2024, 18:395-406

Published Date: 8 February 2024

Comparison of the Pharmacokinetics, Safety, and Tolerability of Two Empagliflozin Formulations in Healthy Korean Subjects

Jiang X, Bae S, Yoon DY, Park SJ, Oh J, Cho JY, Yu KS

Drug Design, Development and Therapy 2023, 17:2137-2145

Published Date: 24 July 2023

Pharmacokinetics, Tolerability and Pharmacogenetics of DA-8031 After Multiple Ascending Doses in Healthy Male Subjects

Hwang S, Lee DY, Cho JY, Chung JY, Jang IJ, Yu KS, Lee S

Drug Design, Development and Therapy 2021, 15:2375-2384

Published Date: 1 June 2021

Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects

Yoo H, Kim Y, Jang IJ, Yu KS, Lee S

Drug Design, Development and Therapy 2020, 14:5179-5187

Published Date: 24 November 2020

Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects

Hwang I, Kim Y, Yoo H, Jang IJ, Yu KS, Lee S

Drug Design, Development and Therapy 2020, 14:4493-4502

Published Date: 23 October 2020

Factors influencing insulin sensitivity during hyperinsulinemic-euglycemic clamp in healthy Korean male subjects

Shin D, Eom YS, Chon S, Kim BJ, Yu KS, Lee DH

Diabetes, Metabolic Syndrome and Obesity 2019, 12:469-476

Published Date: 10 April 2019

Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers

Choi Y, Lee S, Jang IJ, Yu KS

Drug Design, Development and Therapy 2018, 12:2301-2309

Published Date: 24 July 2018

Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic

Sunwoo J, Kim YK, Choi Y, Yu KS, Nam H, Cho YL, Yoon S, Chung JY

Drug Design, Development and Therapy 2018, 12:1707-1714

Published Date: 11 June 2018

Pharmacokinetic characteristics of telaprevir in healthy Korean male subjects and comparisons with Japanese

Choi Y, Yoon S, Matsumoto K, Ohta Y, Lee S, Yu KS, Jang IJ

Drug Design, Development and Therapy 2018, 12:1045-1051

Published Date: 30 April 2018

Pharmacokinetics and tolerability of eletriptan hydrobromide in healthy Korean subjects

Kim YK, Shin KH, Alderman J, Yu KS, Jang IJ, Lee S

Drug Design, Development and Therapy 2018, 12:331-337

Published Date: 19 February 2018

A first-in-human, double-blind, placebo-controlled, randomized, dose escalation study of DWP05195, a novel TRPV1 antagonist, in healthy volunteers

Lee J, Kim BH, Yu KS, Kim HS, Kim JD, Cho JY, Lee S, Gu N

Drug Design, Development and Therapy 2017, 11:1301-1313

Published Date: 24 April 2017

Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects

Shin D, Lee S, Yi S, Yoon SH, Cho JY, Bahng MY, Jang IJ, Yu KS

Drug Design, Development and Therapy 2017, 11:713-723

Published Date: 10 March 2017

Effects of dexamethasone coadministered with oseltamivir on the pharmacokinetics of oseltamivir in healthy volunteers

Jang K, Kim M, Oh J, Lee S, Cho JY, Yu KS, Choi TK, Lee SH, Lim KS

Drug Design, Development and Therapy 2017, 11:705-711

Published Date: 9 March 2017

Pharmacokinetic and pharmacodynamic interactions between metformin and a novel dipeptidyl peptidase-4 inhibitor, evogliptin, in healthy subjects

Rhee SJ, Choi Y, Lee S, Oh J, Kim SJ, Yoon SH, Cho JY, Yu KS

Drug Design, Development and Therapy 2016, 10:2525-2534

Published Date: 10 August 2016

A pharmacokinetic comparison of two voriconazole formulations and the effect of CYP2C19 polymorphism on their pharmacokinetic profiles

Chung H, Lee H, Han H, An H, Lim KS, Lee YJ, Cho JY, Yoon SH, Jang IJ, Yu KS

Drug Design, Development and Therapy 2015, 9:2609-2616

Published Date: 13 May 2015

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects

Hong T, Han S, Lee J, Jeon S, Park GJ, Park WS, Lim KS, Chung JY, Yu KS, Yim DS

Drug Design, Development and Therapy 2015, 9:1233-1245

Published Date: 26 February 2015

Effect of renal function on the pharmacokinetics of fimasartan: a single-dose, open-label, Phase I study

Kim S, Lee J, Shin D, Lim KS, Kim YS, Jang IJ, Yu KS

Drug Design, Development and Therapy 2014, 8:1723-1731

Published Date: 6 October 2014

Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers

Gu N, Park MK, Kim TE, Bahng MY, Lim KS, Cho SH, Yoon SH, Cho JY, Jang IJ, Yu KS

Drug Design, Development and Therapy 2014, 8:1709-1721

Published Date: 6 October 2014

Pharmacokinetics and tolerability of the new second-generation nonnucleoside reverse- transcriptase inhibitor KM-023 in healthy subjects

Cha YJ, Lim KS, Park MK, Schneider S, Bray B, Kang MC, Chung JY, Yoon SH, Cho JY, Yu KS

Drug Design, Development and Therapy 2014, 8:1613-1619

Published Date: 26 September 2014

Predictive performance of gentamicin dosing nomograms

Lee J, Yoon S, Shin D, Han H, An H, Lee J, Lim KS, Yu KS, Lee H

Drug Design, Development and Therapy 2014, 8:1097-1106

Published Date: 16 August 2014

Novel nanocrystal formulation of megestrol acetate has improved bioavailability compared with the conventional micronized formulation in the fasting state

Jang K, Yoon S, Kim SE, Cho JY, Yoon SH, Lim KS, Yu KS, Jang IJ, Lee H

Drug Design, Development and Therapy 2014, 8:851-858

Published Date: 25 June 2014